Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Amerikaanse aandelen   /   Forum Transenterix geopend

Amerikaanse aandelen« Terug naar discussie overzicht

Forum Transenterix geopend

Volgen
344 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 18 »» | Laatste | Omlaag ↓
  12. forum rang 10 DeZwarteRidder 9 augustus 2019 15:50

    TransEnterix, Inc. Reports Operating and Financial Results for the Second Quarter 2019
    August 7, 2019 at 4:05 PM EDT

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aug. 7, 2019-- TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the second quarter of 2019.

    Recent Highlights

    Total revenue of $3.6 million in the second quarter of 2019
    Received Japanese regulatory approval of the Senhance® Surgical System
    Received broad Japanese reimbursement for 98 different procedures, effective July 31, 2019
    AutoLap asset sale and equity sale to bring in a total of $47 million

    “While we were disappointed with our system sales in the quarter, we are encouraged by our operational accomplishments including the monetization of the AutoLap assets and achievement of Japanese regulatory approval and broad reimbursement well ahead of our expectations,” said Todd M. Pope, President, and CEO of TransEnterix. “We are focused on improving commercial execution to drive global system sales in the second half of the year.”

    Commercial and Clinical Update

    In the quarter ended June 30, 2019, the Company sold one Senhance® System, in the EMEA region to an end user hospital.

    On May 28, 2019, the Company announced that it received Japanese regulatory approval for the Senhance Surgical System. The Senhance Surgical System was approved by the Ministry of Health, Labor and Welfare (MHLW) for use in laparoscopy for general surgery, gynecology, and urology.

    On August 1, 2019, the Company announced that the MHLW expert review panel provided reimbursement for procedures performed with the Senhance Surgical System. The reimbursement, which became effective on July 31, 2019, applies to 98 benign and malignant laparoscopic surgeries at reimbursement rates equivalent to traditional laparoscopy in Category A1.

    AutoLap Asset Sale

    On July 10, the Company announced the sale of certain AutoLap® image-based laparoscope positioning system (AutoLap) product and intellectual property assets to Great Belief International Limited (GBIL). The total proceeds to be paid to the Company for these assets is $17 million. In addition, GBIL is making an equity investment of $30.0 million in TransEnterix common stock at $2.00 per share. As a part of the sale agreement, the Company retains ownership of the broader intellectual property portfolio it acquired from M.S.T. - Medical Surgery Technologies in October 2018, and will enter into a cross-license agreement with GBIL under which it gains a license to use the AutoLap-related IP sold, and grants GBIL a non-exclusive license to use additional IP in connection with the AutoLap.

    Second Quarter Financial Highlights

    For the three months ended June 30, 2019, the Company reported revenue of $3.6 million as compared to revenue of $6.4 million in the three months ended June 30, 2018. Revenue in the second quarter of 2019 included $2.7 million in system sales, $560 thousand in instruments and accessories, and $342 thousand in services. The $2.7 million in system sales revenue includes the recognition of $1.3 million from a system sold in 2017 for which revenue was deferred until its first clinical use, which occurred in the second quarter.

    For the three months ended June 30, 2019, total net operating expenses were $22.2 million, as compared to $18.5 million in the three months ended June 30, 2018.

    For the three months ended June 30, 2019, net loss was $20.2 million, or $0.09 per basic share, as compared to a net loss of $34.2 million, or $0.17 per basic share, in the three months ended June 30, 2018.

    For the three months ended June 30, 2019, adjusted net loss was $19.2 million, or $0.09 per basic share, as compared to an adjusted net loss of $11.7 million, or $0.06 per basic share in the three months ended June 30, 2018, after adjusting for the following charges: change in fair value of warrant liabilities, amortization of intangible assets, change in fair value of contingent consideration, loss on debt extinguishment, acquisition-related costs and the loss (gain) on the sale of the SurgiBot assets. Adjusted net loss is a non-GAAP measure. See the reconciliation to GAAP below.

    The Company had cash and cash equivalents, restricted cash and short term investments of approximately $34.0 million as of June 30, 2019. The Company believes that existing cash and short term investments and the expected proceeds from the AutoLap transaction are sufficient to support the business into mid-2020.

    Conference Call

    TransEnterix, Inc. will host a conference call on Wednesday, August 7, 2019, at 4:30 p.m. ET to discuss its second quarter 2019 operating and financial results. To listen to the conference call on your telephone, please dial (844) 804-5261 for domestic callers or (612) 979-9885 for international callers and reference conference ID 4293967 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link ir.transenterix.com/events.cfm. The replay will be available on the Company's website.

    About TransEnterix

    TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU, and select other countries. For more information, visit www.transenterix.com.
  17. [verwijderd] 9 september 2019 07:25
    quote:

    Transenterix56 schreef op 16 april 2019 11:23:

    Heeft iets langer geduurd als gewenst maar heb informatie ontvangen inmiddels. Ik kan niet exact aangeven wat de ontwikkelingen zijn maar we kunnen als longers rustig blijven zitten. Zelfs nog iets bijkopen als mogelijk is. Ik kijk relaxed de toekomst tegen moet. Als alles gerealiseerd wordt zijn er spectaculaire ontwikkelingen te verwachten!!!!
    Licht eindelijk eens een tipje van de sluier op!!!!
344 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 18 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
NX FILTRATION 4,930 +0,27 +5,91%
SHELL PLC 30,815 +0,69 +2,29%
AZERION 1,300 +0,02 +1,56%
Flow Traders 21,040 +0,28 +1,35%
ING 15,674 +0,12 +0,77%
ABN AMRO BANK N.V. 15,190 +0,06 +0,43%
Basic-Fit 22,640 +0,08 +0,35%
SBM Offshore 16,770 +0,02 +0,12%
Fagron 18,540 +0,02 +0,11%
Fugro 21,060 +0,02 +0,10%
ArcelorMittal 22,680 +0,01 +0,04%
Accsys 0,599 0,00 0,00%
NSI 19,800 0,00 0,00%
Vastned 24,650 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
ASMI 512,200 -32,40 -5,95%
Galapagos 24,820 -1,50 -5,70%
JUST EAT TAKEAWAY 10,475 -0,48 -4,34%
Alfen N.V. 12,255 -0,51 -4,03%
BESI 97,940 -4,01 -3,93%
FASTNED 21,850 -0,85 -3,74%
Pharming 0,769 -0,03 -3,45%
Avantium 2,385 -0,09 -3,44%
ALLFUNDS GROUP 5,625 -0,20 -3,35%
Vopak 42,240 -1,32 -3,03%
DSM FIRMENICH AG 109,100 -3,20 -2,85%
BAM 4,244 -0,10 -2,26%
RENEWI 7,230 -0,16 -2,17%
Kendrion 10,920 -0,24 -2,15%
ADYEN NV 1.406,400 -29,60 -2,06%
ASML 621,200 -12,80 -2,02%
Brunel 8,860 -0,18 -1,99%
PostNL 1,103 -0,02 -1,96%
SIGNIFY NV 22,520 -0,42 -1,83%
IMCD 146,050 -2,70 -1,82%
Air France-KLM 9,028 -0,16 -1,72%
Sligro 11,460 -0,20 -1,72%
RELX 42,620 -0,74 -1,71%
Wereldhave 14,160 -0,24 -1,67%
TomTom 5,015 -0,09 -1,67%
ForFarmers 3,275 -0,06 -1,65%
ASCX 1.207,68 -19,23 -1,57%
ACOMO 17,400 -0,26 -1,47%
WDP 21,820 -0,32 -1,45%
AMX 877,91 -12,87 -1,44%
CTP 15,320 -0,22 -1,42%
UMG 23,080 -0,33 -1,41%
JDE PEET'S 20,700 -0,28 -1,33%
AALBERTS NV 33,160 -0,44 -1,31%
UNILEVER PLC 56,220 -0,72 -1,26%
Heineken 75,500 -0,96 -1,26%
KPN 3,593 -0,04 -1,24%
OCI 11,165 -0,14 -1,19%
B&S Group SA 4,630 -0,05 -1,17%
Corbion 23,020 -0,26 -1,12%
TKH 37,300 -0,42 -1,11%
Eurocommercial Properties 23,350 -0,25 -1,06%
INPOST 17,930 -0,17 -0,94%
PROSUS 38,745 -0,34 -0,87%
ASR Nederland 43,570 -0,37 -0,84%
AEX 874,18 -7,09 -0,80%
THEON INTERNAT 8,790 -0,07 -0,79%
Arcadis 63,650 -0,50 -0,78%
Nedap N.V. 55,000 -0,40 -0,72%
Van Lanschot Kempen NV 42,050 -0,30 -0,71%
Aegon 5,806 -0,04 -0,68%
Wolters Kluwer 154,700 -1,05 -0,67%
Sif Holding 13,800 -0,08 -0,58%
AMG Critical Materials N.V. 15,570 -0,09 -0,57%
RANDSTAD NV 42,350 -0,22 -0,52%
Aperam 24,940 -0,12 -0,48%
Philips Koninklijke 24,120 -0,11 -0,45%
Akzo Nobel 58,480 -0,24 -0,41%
CM.COM 6,500 -0,02 -0,31%
Ahold Delhaize 30,310 -0,08 -0,26%
HEIJMANS KON 24,750 -0,05 -0,20%
EBUSCO HOLDING 2,190 0,00 -0,11%
EXOR NV 97,200 -0,10 -0,10%
NN Group 45,190 -0,01 -0,02%
vlag naam koers verschil relatief verschil
AEX 874,18 -7,09 -0,80%
AEX GR 3.418,42 -27,13 -0,79%
Germany40^ 19.081,70 +4,16 +0,02%
FTSE 100 8.110,10 -49,53 -0,61%
EURO50 4.831,38 -46,62 -0,96%
US30^ 41.779,40 0,00 0,00%
Nasd100^ 19.912,00 0,00 0,00%
US500^ 5.705,75 0,00 0,00%
Japan225^ 38.355,10 0,00 0,00%
VD-NEW 19,73 +1,43 +7,80%
#/^ Index indications calculated real time, zie disclaimer